



# Preparation and high resolution analysis of a Fab

**Intellectual Property Notice:** The Biopharma business of GE Healthcare was acquired by Danaher on 31 March 2020 and now operates under the Cytiva™ brand. Certain collateral materials (such as application notes, scientific posters, and white papers) were created prior to the Danaher acquisition and contain various GE owned trademarks and font designs. In order to maintain the familiarity of those materials for long-serving customers and to preserve the integrity of those scientific documents, those GE owned trademarks and font designs remain in place, it being specifically acknowledged by Danaher and the Cytiva business that GE owns such GE trademarks and font designs.

## cytiva.com

GE and the GE Monogram are trademarks of General Electric Company.  
Other trademarks listed as being owned by General Electric Company contained in materials that pre-date the Danaher acquisition and relate to products within Cytiva's portfolio are now trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.  
Cytiva and the Drop logo are trademarks of Global Life Sciences IP Holdco LLC or an affiliate.  
All other third-party trademarks are the property of their respective owners.  
© 2020 Cytiva  
All goods and services are sold subject to the terms and conditions of sale of the supplying company operating within the Cytiva business. A copy of those terms and conditions is available on request. Contact your local Cytiva representative for the most current information.  
For local office contact information, visit [cytiva.com/contact](https://www.cytiva.com/contact)



# Preparation and high resolution analysis of a Fab

Jens Widehammar and Gustav Rodrigo


GE Healthcare Bio-Sciences AB, Björkgatan 30, SE-751 84 Uppsala, Sweden

## Introduction


Antibody fragments are getting increased attention in research use due to their small size and lower immunogenicity (relative to intact antibodies).

In this work Fab was produced by papain cleavage of a purified monoclonal antibody (mAb) followed by

purification on MabSelect Sure™ and Capto™ L resins (Protein A and Protein L immobilized to high flow agarose, respectively). Fractions from the different steps were analyzed with a new generation size exclusion chromatography (SEC) resin, Superdex™ 200 Increase.



**Fig 1.** SEC analyses of (A) Purified mAb (B) Flowthrough containing Fab, and (C) Purified Fab. Affinity chromatography run on HiTrap 5 mL MabSelect Sure and Protein L. Buffers and flow rates according to resins instructions. All SEC analyses were run on Superdex 200 Increase 10/300 GL with PBS, 0.5 mL/min and 50 µL sample on ÄKTA™ pure chromatography systems.



**Fig 2.** Overlay of individual SEC analyses of mAb, Fab, and Fc fragments. For comparative purposes, the curves have been normalized against the peak height of each monomer species.

## Conclusions

- HiTrap MabSelect Sure and HiTrap Protein L enable a simplified workflow to produce Fab by papain digestion of mAb
- High resolution power of Superdex 200 Increase allows baseline separation between monomer and aggregates from both mAb and Fab
- Broad separation range ( $M_r$  10 000 to  $M_r$  600 000) with optimized resolution for antibodies ( $M_r$  100 000 to  $M_r$  300 000) allows separation of a large number of different biomolecules